TidalSense, known as The respiratory intelligence company, is carving a niche in the Biotechnology and Health Care industries. Founded in 2013 as Cambridge Respiratory Innovations, the company operates out of its headquarters in the United Kingdom.
TidalSense develops cutting-edge respiratory technology solutions, underpinned by its patented sensor technology, N-Tidal. This innovation delivers high precision and rapid CO2 sampling, offering unique insights into lung physiology. Their technology stands out for being the first of its kind in clinical medicine, marking significant advancements in AI-driven diagnostic and monitoring solutions for respiratory care.
The company secured a £2.54M Seed Round investment on 16 May 2023, with backing from reputable investors such as Foresight Group, Downing Ventures, and Business Growth Fund. This investment underscores faith in TidalSense's disruptive potential in respiratory medicine.